Research

Mixed

Metformin, alpha-lipoic acid (ALA), and GLP-1 receptor agonists are effective, complementary pharmacological interventions for managing metabolic syndrome, with metformin serving as the universal first-line treatment due to its safety, low cost, and wide availability.

For patients with Metabolic Syndrome, especially in crisis or resource-limited settings, start with metformin as the primary treatment due to its proven safety, low cost, and wide availability. Add alpha-lipoic acid (ALA) to target oxidative stress and insulin sensitivity, and consider GLP-1 agonists if cardiovascular risk is high and resources allow. Simplify regimens and use telemedicine to support adherence, as stress and disruption are major barriers to care.

GoodSupportsHIGH confidence
These therapies have been shown to improve fasting glucose, glycated hemoglobin (HbA1c), body weight, lipid profiles, and inflammatory markers... Metformin is consistently recognized as a universal first-line treatment... ALA... improves insulin sensitivity and reduces markers of oxidative stress... GLP-1 receptor agonists also provide cardiovascular protection
Olena Mykhailenko et al. · Galician Medical Journal · 2025

Why this rating

Based on a narrative review of 78 peer-reviewed publications including RCTs and meta-analyses, though not a single primary RCT.

Source

Pharmacological Management of Metabolic Syndrome in Crisis Settings: A Narrative Review and Three-Axis Model

Olena Mykhailenko et al. · Galician Medical Journal · 2025

DOI 10.21802/e-gmj2025-a27

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →